Preparation and study of the inhibitory effect of nano-niosomes containing essential oil from artemisia absinthium on amyloid fibril formation

Document Type: Research Paper


Department of Biomedical Engineering, Meybod University, Meybod, Iran


Objective(s): Artemisia absinthium is an aromatic, perennial small shrub that shows multiple medical benefits, including anticancerous, neuroprotective, antifungal, hepatoprotective, antidepressant and antioxidant properties. One of the effective approaches to treat Alzheimer’s disease is targeting amyloid aggregation by antiamyloid drugs. In the current research study, an excellent grouping of niosomal, lipid nano-carriers drugs containing artemisia absinthium is advanced and characterized to inhibit amyloid aggregation.
Materials and Methods: Niosomal vesicles were made employing phosphatidylcholine, span 60, cholesterol and DSPE-PEG2000 by the thin-film method. Then artemisia absinthium was loaded into the niosomes. Their physico-chemical attributes were analyzed utilizing Zeta-Sizer, FTIR, and SEM, and the amount of drug release was measured at 37° C. Finally, the inhibitory effect of artemisia absinthium that loaded niosomal vesicles on the aggregation of amyloid-β peptides was investigated using Thioflavin T fluorescence measurements and atomic force microscopy.
Results: Niosomes containing artemisia absinthium have a size of 174±2.56nm, the encapsulation efficiency of 66.73%, zeta potential of -26.5±1/42 mV and polydispersity index (PDI) of 0.373±0/02. The release of the drug is controlled in this nano-carrier and FTIR and SEM investigations showed that the drug and nano-carrier did not interact and their particles had a spherical structure. In the end, the inhibitory effect of artemisia absinthium that loaded niosomal vesicles on the aggregation of amyloid-β peptides was examined and confirmed through Thioflavin T fluorescence measurements and atomic force microscopy.
Conclusion: Meanwhile, the findings of the current study, confirm the appropriate physicochemical features of the system, a slow-release system, show that this nano-carrier inhibits amyloid aggregation, thus, the nano-niosomes containing essential oil from artemisia absinthium has the capability to preclude amyloid development.


1.Ansari M, Habibi-Rezaei M, Salahshour-Kordestani S, Moosavi Movahedi AA, Poursasan N. Prevention of serum albumin glycation/fibrillation by β-cyclodextrin functionalized magnetic nanoparticles. Protein Pept Lett. 2015; 22( 7): 594-600.
2-Ansari M, Habibi-Rezaei M, Salahshour-Kordestani S, Ferdousi M, Movahedi AA. An investigation on the effect of β-CD modified Fe3O4 magnetic nanoparticles on aggregation of amyloid b peptide (25-35). Mater Technol. 2016; 31(6): 315-321.
3.Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006; 27(4):570-575.
4.Murphy RM. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. BBA-Biomembranes. 2007;1768(8):1923-1934.
5.Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, Huang K. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. BBA-Gen Subjects. 2013; 1830(10): 4860-4871.
6.Mirzaie Z, Ansari M, Kordestani SS, Rezaei MH, Mozafari M. Preparation and characterization of curcumin‐loaded polymeric nanomicelles to interference with amyloidogenesis through glycation method. Biotechnol Appl Bioc. 2019;66(4): 537-544.
7.Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci. 2001; 24(4): 219-224.
8.Thal DR, Walter J, Saido TC, Fändrich M. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathol. 2015;129(2):167-182.
9.Hamley IW. The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization. Chem Rev. 2012;112(10):5147-92.
10. Eisele YS, Monteiro C, Fearns C, Encalada SE, Wiseman RL, Powers ET, Kelly JW. Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov. 2015; 14(11): 759.
11.S Sood A, Abid M, Sauer C, Hailemichael S, Foster M, Török B, Török M. Disassembly of preformed amyloid beta fibrils by small organofluorine molecules. Bioorg Med Chem Lett. 2011; 21(7): 2044-2047.
12. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, Lindman S, Minogue AM, Thulin E, Walsh DM, Dawson KA, Linse S. Inhibition of amyloid β protein fibrillation by polymeric nanoparticles. J Am Chem Soc. 2008; 130(46): 15437-15443.
13. Ahn M, Lee BI, Chia S, Habchi J, Kumita JR, Vendruscolo M, Dobson CM, Park CB. Chemical and mechanistic analysis of photodynamic inhibition of Alzheimer’s β-amyloid aggregation. Chem Commun. 2019; 55(8): 1152-1155.
14.Härd T, Lendel C. Inhibition of amyloid formation. J Mol Biol. 2012; 421(4-5): 441-465.
15.Arora A, Ha C, Park CB. Inhibition of insulin amyloid formation by small stress molecules. Febs Lett. 2004; 564(1-2): 121-125.
16.Anand BG, Dubey K, Shekhawat DS, Kar K. Capsaicin-coated silver nanoparticles inhibit amyloid fibril formation of serum albumin. Biochemistry-us. 2016; 55(24): 3345-3348.
17. Ke PC, Pilkington EH, Sun Y, Javed I, Kakinen A, Peng G, Ding F, Davis TP. Mitigation of Amyloidosis with Nanomaterials. Adv Mater. 2019: 1901690.
18. Lu J, Cao Q, Wang C, Zheng J, Luo F, Xie J, Li Y, Ma X, He L, Eisenberg D, Nowick J. Structure-based peptide inhibitor design of amyloid-aggregation. Front Mol Neurosci. 2019; 12: 54.
19.Vogel MC, Kumar S, Maity D, Magzoub MM, Hamilton AD. Inhibition of Zinc-Mediated Amyloid Beta Aggregation and Cytotoxicity by Alpha Helix Mimetics. Biophys J. 2019; 116(3): 479a-80a.
20.Gao N, Du Z, Guan Y, Dong K, Ren J, Qu X. Chirality-selected chemical modulation of amyloid aggregation. J Am Chem Soc. 2019; 141(17): 6915-6921.
21.Pai AS, Rubinstein I, Önyüksel H. PEGylated phospholipid nanomicelles interact with β-amyloid (1–42) and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides. 2006; 27(11): 2858-2866.
22.Saraiva AM, Cardoso I, Saraiva MJ, Tauer K, Pereira MC, Coelho MA, Möhwald H, Brezesinski G. Randomization of Amyloid‐β‐Peptide (1‐42) Conformation by Sulfonated and Sulfated Nanoparticles Reduces Aggregation and Cytotoxicity. Macromol Biosci. 2010; 10(10): 1152-1163.
23.Kim JE, Lee M. Fullerene inhibits β-amyloid peptide aggregation. Biochem Bioph Res Co. 2003;303(2):576-9.
24. Saraiva AM, Cardoso I, Pereira MC, Coelho MA, Saraiva MJ, Möhwald H, Brezesinski G. Controlling Amyloid‐β Peptide (1–42) Oligomerization and Toxicity by Fluorinated Nanoparticles. Chembiochem. 2010; 11(13): 1905-1913.
25.Xiao L, Zhao D, Chan W-H, Choi MM, Li H-W. Inhibition of beta 1–40 amyloid fibrillation with N-acetyl-l-cysteine capped quantum dots. Biomaterials. 2010; 31(1): 91-98.
26. Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, Lee SE. Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid. J Agr Food Chem. 2005; 53(22): 8537-8541.
27.Sun L-j, Qu L, Yang R, Yin L, Zeng H-j. Cysteamine functionalized MoS2 quantum dots inhibit amyloid aggregation. Int J Biol Macromol. 2019; 128: 870-876.
28. Apaijai N, Moisescu DM, Palee S, McSweeney CM, Saiyasit N, Maneechote C, Boonnag C, Chattipakorn N, Chattipakorn SC. Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation. J Am Heart Assoc. 2019; 8(2): e010838.
29.Sharma V, Ghosh KS. Inhibition of Amyloid Fibrillation by Small Molecules and Nanomaterials: Strategic Development of Pharmaceuticals Against Amyloidosis. Protein Peptide Lett. 2019; 26(5): 315-323.
30. Dubey K, Anand BG, Badhwar R, Bagler G, Navya PN, Daima HK, Kar K. Tyrosine-and tryptophan-coated gold nanoparticles inhibit amyloid aggregation of insulin. Amino Acids. 2015; 47(12): 2551-2560.
31.Dubey K, Anand BG, Shekhawat DS, Kar K. Eugenol prevents amyloid formation of proteins and inhibits amyloid-induced hemolysis. Sci Rep-uk. 2017; 7: 40744.
32.Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP. The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry-us. 2010; 49(37): 8127-8133.
33.Pang B, Bian X, Xing J, Liu S, Liu Z, Song F. Effects of lithospermic acid on hIAPP aggregation and amyloid-induced cytotoxicity by multiple analytical methods. BBA-proteins Proteom. 2020; 1868(1): 140283.
34.Borriello M, Iannuzzi C, Sirangelo I. Pinocembrin Protects from AGE-Induced Cytotoxicity and Inhibits Non-Enzymatic Glycation in Human Insulin. Cells. 2019; 8(5): 385.
35. Divino da Rocha M, Pereira Dias Viegas F, Cristina Campos H, Carolina Nicastro P, Calve Fossaluzza P, Alberto Manssour Fraga C, J Barreiro E, Viegas C. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. Cns Neurol Disord-dr. 2011; 10(2): 251-270.
36.Fang L, Gou S, Fang X, Cheng L, Fleck C. Current progresses of novel natural products and their derivatives/analogs as anti-Alzheimer candidates: an update. Mini-rev Med Chem. 2013; 13(6): 870-887.
37.Cairo CW, Strzelec A, Murphy RM, Kiessling LL. Affinity-based inhibition of β-amyloid toxicity. Biochemistry-us. 2002; 41(27): 8620-8629.
38.Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci. 2013; 14(6): 12411-12457.
39. Bartelds R, Nematollahi MH, Pols T, Stuart MC, Pardakhty A, Asadikaram G, Poolman B. Niosomes, an alternative for liposomal delivery. Plos One. 2018; 13(4): e0194179.